[Skip to Content]
[Skip to Content Landing]
Views 1,940
Citations 0
Research Letter
October 28, 2019

Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients

Author Affiliations
  • 1Department of Neurology, Mayo Clinic, Rochester, Minnesota
  • 2Department Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
  • 3Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota
  • 4Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota
JAMA Neurol. 2020;77(2):257-259. doi:10.1001/jamaneurol.2019.3656

Myelin oligodendrocyte glycoprotein (MOG)–IgG is a biomarker associated with central nervous system–demyelinating disorders termed MOG-IgG–associated disorders. These disorders have overlapping clinical features, including optic neuritis and myelitis, with aquaporin-4 (AQP4)–IgG–positive neuromyelitis optica spectrum disorders. These disorders are hypothesized to be biologically distinct; AQP4-IgG–positive neuromyelitis optica spectrum disorders are autoimmune astrocytopathies, whereas MOG-IgG–associated disorders are postulated to be autoimmune oligodendrocytopathies.1 Despite their immunopathogenic differences, there are rare reports of patients with dual positivity of MOG-IgG and AQP4-IgG.2,3 We aimed to determine the frequency, sex ratio, and coexistence of glial antibodies (AQP4-IgG and MOG-IgG) in adults and children undergoing evaluation for suspected central nervous system–demyelinating diseases.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×